Key Highlights

  • KPTI was down 7.14% at USD 0.1040 in pre-market trading on November 3, 2026.
  • The company filed voluntary Chapter 11 petitions on November 2, 2026, in the Southern District of Texas.
  • Existing lenders committed up to USD 55 million of debtor-in-possession financing, subject to court approval.
  • The restructuring plan provides no distribution to common stockholders, according to an 8-K.
  • Fiscal 2025 Revenue was USD 146.1 million with a net loss of USD 196.0 million.

Pre-market trading after the Bankruptcy filing (down USD 0.0080, 7.14%)

Karyopharm Therapeutics (NASDAQ:KPTI) was down 7.14% at USD 0.1040 in pre-market trading on November 3, 2026. That implies a Monday November 2, 2026 close of roughly USD 0.1120 (calculated), far below the USD 0.6620 close cited for October 30, 2026 in an earlier review of the stock.

The move follows a company announcement made on November 2, 2026.

What the November 2 filing says

In an 8-K, the company said it filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas. It also signed a Restructuring Support Agreement with existing lenders, noteholders and other stakeholders. The agreement provides for a Merger between Ayrmid Ltd. and a reorganized Karyopharm.

Ayrmid is the lead bidder, and court-approved bidding procedures would allow other parties to submit competing bids. The transaction is expected to close in the first quarter of 2027, subject to the conditions of the plan. The company said it expects operations to continue in the ordinary course during the process and remains focused on its multiple myeloma and myelofibrosis programs.

Business background and recent results

Karyopharm is a commercial-stage oncology company that markets XPOVIO, an oral therapy for certain blood cancers, and develops related candidates.

For fiscal 2025, the company reported revenue of USD 146.1 million, a net loss of USD 196.0 million and Operating Cash Flow of negative USD 75.4 million. Second-quarter 2026 results were released on August 13, 2026. An 8-K dated October 22, 2026 had extended a creditor forbearance period to November 1, 2026.

Balance sheet and risks

The prepackaged plan provides no distribution to holders of common stock or convertible preferred stock, and the company expects existing Equity to have no value.

The 8-K also cites an expected delisting of the common stock from the Nasdaq Global Select Market, although no delisting had been confirmed in the filing. As a penny stock, KPTI can swing sharply on thin liquidity, and quoted prices in extended hours may differ widely from regular-session trades.

What to watch next

Developments to follow include court approval of the USD 55 million debtor-in-possession financing, the bidding procedures and any competing offers for the company or its assets. A formal Nasdaq delisting notice and the timing of third-quarter 2026 results are other markers.